Found: 10
Select item for more details and to access through your institution.
Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L.
- Published in:
- Chemical Biology & Drug Design, 2012, v. 80, n. 6, p. 971, doi. 10.1111/cbdd.12050
- By:
- Publication type:
- Article
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
- Published in:
- Biopharmaceutics & Drug Disposition, 2014, v. 35, n. 4, p. 237, doi. 10.1002/bdd.1889
- By:
- Publication type:
- Article
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
- Published in:
- PLoS ONE, 2014, v. 9, n. 12, p. 1, doi. 10.1371/journal.pone.0111840
- By:
- Publication type:
- Article
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
- Published in:
- 2017
- By:
- Publication type:
- Correction Notice
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
- Published in:
- PLoS ONE, 2016, v. 11, n. 7, p. 1, doi. 10.1371/journal.pone.0158888
- By:
- Publication type:
- Article
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
- Published in:
- Nature Chemical Biology, 2015, v. 11, n. 6, p. 432, doi. 10.1038/nchembio.1810
- By:
- Publication type:
- Article
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
- Published in:
- FEBS Letters, 2011, v. 585, n. 19, p. 3011, doi. 10.1016/j.febslet.2011.08.018
- By:
- Publication type:
- Article
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
- Published in:
- Nature Chemical Biology, 2012, v. 8, n. 11, p. 890, doi. 10.1038/nchembio.1084
- By:
- Publication type:
- Article